Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia
| Autor: | Nobuto Shibata, Narimasa Katsuta, Yusuke Suzuki, Hitoshi Maeshima, Yasuhiko Tomino, Heii Arai, Ryoko Higashiyama, Tomohito Gohda, Motoyuki Higa, Shohei Nishimon, Toru Nakamura, Mayu Takeda, Yuri Hotta, Sho-ichi Yamagishi, Ryo Hanzawa, Yuto Takebayashi, Takahiro Sannohe, Masayoshi Takeuchi, Tohru Ohnuma |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Glycation End Products Advanced Male Vitamin medicine.medical_specialty Adolescent Receptor for Advanced Glycation End Products Glyceraldehyde chemistry.chemical_compound Internal medicine medicine Humans Receptors Immunologic Pentosidine Receptor Chlorpromazine Pyridoxal Aged business.industry General Neuroscience Neurotoxicity Middle Aged medicine.disease Endocrinology chemistry Schizophrenia Case-Control Studies Advanced glycation end-product Female business Biomarkers medicine.drug |
| Zdroj: | Neuroscience Letters. 593:51-55 |
| ISSN: | 0304-3940 |
| DOI: | 10.1016/j.neulet.2015.03.002 |
| Popis: | Recent cross-sectional and longitudinal studies indicate that measurements of peripheral blood carbonyl stress markers such as the advanced glycation end product (AGE) pentosidine and the reactive carbonyl-detoxifying B6 vitamin pyridoxal could be used as therapeutic biological markers in subpopulations of schizophrenia patients. Glyceraldehyde-derived AGEs (Glycer-AGE) have strong neurotoxicity, and soluble receptors for AGEs (sRAGE) may ameliorate the effects of AGEs. In the present study, we measured Glycer-AGEs and sRAGE levels to determine their potential as diagnostic, therapeutic, or clinical biological markers in patients with schizophrenia. After enrollment of 61 admitted Japanese patients with acute schizophrenia and 39 healthy volunteers, 54 patients were followed up from the acute stage to remission. Serum biomarkers were measured in blood samples taken before breakfast using competitive enzyme-linked immunosorbent assays, and Glycer-AGEs were significantly higher and sRAGE levels were significantly lower in patients with acute schizophrenia than in healthy controls. Glycer-AGEs/sRAGE ratios were also higher in schizophrenia patients and were stable during the clinical course. Furthermore, discriminant analyses confirmed that Glycer-AGEs and Glycer-AGEs/sRAGE ratios are significant diagnostic markers for schizophrenia, and distinguished between patients and healthy controls in 70.0% of cases. However, these markers of carbonyl stress were not correlated with clinical features, including disease severity, or with daily chlorpromazine doses. These data indicate the potential of Glycer-AGEs, RAGEs, and their relative ratios as diagnostic markers for patients with schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect